JP5709522B2 - 新規イメージング法 - Google Patents

新規イメージング法 Download PDF

Info

Publication number
JP5709522B2
JP5709522B2 JP2010534461A JP2010534461A JP5709522B2 JP 5709522 B2 JP5709522 B2 JP 5709522B2 JP 2010534461 A JP2010534461 A JP 2010534461A JP 2010534461 A JP2010534461 A JP 2010534461A JP 5709522 B2 JP5709522 B2 JP 5709522B2
Authority
JP
Japan
Prior art keywords
formula
compound
contrast agent
group
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506273A (ja
JP2011506273A5 (https=
Inventor
チェッティビ、サラ
ニュートン、ベン
ソルバッケン、マグネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2011506273A publication Critical patent/JP2011506273A/ja
Publication of JP2011506273A5 publication Critical patent/JP2011506273A5/ja
Application granted granted Critical
Publication of JP5709522B2 publication Critical patent/JP5709522B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2010534461A 2007-11-19 2008-11-19 新規イメージング法 Expired - Fee Related JP5709522B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98884007P 2007-11-19 2007-11-19
US60/988,840 2007-11-19
GBGB0722650.9A GB0722650D0 (en) 2007-11-19 2007-11-19 Novel imaging method
GB0722650.9 2007-11-19
PCT/EP2008/065824 WO2009071444A2 (en) 2007-11-19 2008-11-19 Novel imaging method

Publications (3)

Publication Number Publication Date
JP2011506273A JP2011506273A (ja) 2011-03-03
JP2011506273A5 JP2011506273A5 (https=) 2014-01-09
JP5709522B2 true JP5709522B2 (ja) 2015-04-30

Family

ID=38896533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534461A Expired - Fee Related JP5709522B2 (ja) 2007-11-19 2008-11-19 新規イメージング法

Country Status (8)

Country Link
US (1) US8834843B2 (https=)
EP (1) EP2219681A2 (https=)
JP (1) JP5709522B2 (https=)
CN (1) CN101951964B (https=)
BR (1) BRPI0820430A2 (https=)
GB (1) GB0722650D0 (https=)
RU (1) RU2505316C2 (https=)
WO (1) WO2009071444A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571486C1 (ru) * 2014-11-05 2015-12-20 Общество с ограниченной ответственностью "ДИАМЕД" Способ визуализации воспалений
EP3967704A4 (en) * 2019-06-11 2022-08-31 FUJIFILM Corporation CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATOR MATERIAL AND CULTURE MEDIUM

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
ATE399542T1 (de) * 2003-10-01 2008-07-15 Merck Patent Gmbh Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
EP1833512A1 (en) 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
WO2006115416A2 (en) 2005-04-25 2006-11-02 Ge Healthcare As Liposomes
CA2663749A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007148074A1 (en) 2006-06-21 2007-12-27 Hammersmith Imanet Limited Chemical methods and apparatus

Also Published As

Publication number Publication date
GB0722650D0 (en) 2007-12-27
CN101951964B (zh) 2013-05-29
CN101951964A (zh) 2011-01-19
JP2011506273A (ja) 2011-03-03
WO2009071444A9 (en) 2009-10-01
WO2009071444A2 (en) 2009-06-11
US20100316565A1 (en) 2010-12-16
EP2219681A2 (en) 2010-08-25
US8834843B2 (en) 2014-09-16
WO2009071444A3 (en) 2009-12-23
BRPI0820430A2 (pt) 2015-05-26
RU2010119187A (ru) 2011-12-27
RU2505316C2 (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
CN101454026B (zh) 成像剂
JP5308829B2 (ja) 癌の画像化および処置
US20080267882A1 (en) Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy
CZ20032564A3 (cs) Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků
WO2019092242A1 (en) A double-labeled probe for molecular imaging and use thereof
JP2011520971A (ja) ガストリン放出ペプチド化合物
KR20220152322A (ko) 생체내 알파-v-베타-6-인테그린 접근을 위한 환형 펩타이드 및 그의 컨쥬게이트
CN109316609B (zh) 选择患者的方法
US20250066417A9 (en) New peptide-based diagnostic and therapeutic agents
JP5709522B2 (ja) 新規イメージング法
JP2008528672A (ja) カスパーゼ−３基質含有造影剤
WO2023104794A1 (en) Linker technology for reduced renal retention
US20240115744A1 (en) Fibrin-binding compounds for imaging and treatment
JP2008509921A (ja) 内皮特異的な生体内伝達のターゲティング剤としての熱ショックタンパク質
JP7816883B2 (ja) 線維症の診断および／またはモニタリングに使用するための化合物
AU2010258599B2 (en) PET imaging of fibrogenesis
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
WO2026027771A1 (en) Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof
AU2009272810A1 (en) Treatment monitoring

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131108

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150303

R150 Certificate of patent or registration of utility model

Ref document number: 5709522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees